Clinical Study Of Fuxinning Capsule For Treating Ventricular Premature Complexes

Clinical Study of Fuxinning Capsule fOr Treating VentricuIarPremature ComplexesPostgraduate; Han QianguoTutor: Chen MeiliuaMajor f Intemal medicine of TCMansnaTBackgroud: Ventricular premature complexes (VPC) are the mostcommon arrhytIunia in clinic. At present, there are many antiarrhythIniadrugs fOr VPC, though. they have some side etTects, more or less, whichrestfict their safely uSing. Thefl, some controversies on treating VPC ornot still exist in clinic by now So, developping and objectiveIyevaluating effective and less side effectS new drugs is a vital way to solvethe problems.Objcctivcs: To Observe efficacy and adverse reactions of FuxinningCaPsule fOr treating palpitation (VPC) of Qi and Yn deficiency onclinical symPtoms' frequencies of VPC and cardiac functions And takingWenxin Particle as the control, tO objectively evaluate the efticacy andsafety of Fuxboing CaPsule fOr VPC.Paticnt8 and mcthods: 60 patients with VPC And the study andwere randomized to contrOl and treatmeflt groups, 30 cases in each. Thetredrient group was given Fuxliming Capsule, 4 pills one time and 3tdries each day The control was given Wenxin Particle, l pack one timeand 3 thaes each day The treatment duration was 4 weeks. The studywas made as a randomized dOuble blind control triaI. The degree ofarrhythInia and the treating effects are assessed with dguamicelectrocardiograPh (DCG) and dOPpler echocardiograPhy andelectrocardiogram (ECG) at the beginning and end of the trialrespectively The conditions of blood, urine, excrement, the liver andrenal fndctions were tested in labofatOry The changes of heart fate andrhythm. symptoms' blood pressure1 tongue and pulse conditons werenoted down. The cIinicaI treating effectS and their beginning andmaintaining time were assessed with the methods of grade score andl.described in words. The abnormalities after the treatment were illustrated in words. Finally, the science of statistics was employed to deal with the data.Results:The frequencies of VPC decreased markedly in both groups at the end of the trial. Difference was significant between the beginning and the end of the trial (PO.05) between the two groups. The heart rate~ P-R interval and Q-T interval at the end of the trial had no obvious changes from the beginning of the trial, and the difference was not significant (P>O.05); Cardial functions were significantly improved but difference between the two groups was not significant (P>O.05); The blood pressure had not changed during the treatment. The clinical symptoms were improved strikingly, and the difference was significant (P